Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...

About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D ...

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Revolution Medicines (RVMD) to $64 from $78 and keeps a Buy rating on the ...

Revolution Medicines (NASDAQ:RVMD – Free Report) had its price objective cut by Stifel Nicolaus from $78.00 to $64.00 in a research report released on Tuesday,Benzinga reports. They currently have a ...

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ...

1 Day RVMD -1.97% DJIA -1.69% S&P 500 -1.97% Health Care/Life Sciences 0.11% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Revolution Medicines, Inc. (NASDAQ:RVMD), a biotechnology company with a market capitalization of $7.3 billion focused on developing novel therapies for cancer, has been making significant strides in ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS ...

In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against the other debt free mid cap stocks. Debt-free mid-cap stocks currently offer ...